Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
Harvard Business School
Moodys
Accenture
UBS
Teva

Generated: April 25, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,265,119

« Back to Dashboard

Which drugs does patent 7,265,119 protect, and when does it expire?

Patent 7,265,119 protects CHANTIX and is included in one NDA.

Protection for CHANTIX has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has sixty-one patent family members in forty-eight countries.

Summary for Patent: 7,265,119
Title:Tartrate salts of 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4.9]-hexadeca-2(11),3,5,7- ,9-pentaene and pharmaceutical compositions thereof
Abstract:The present invention is directed to the tartrate salts of 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]-hexadeca-2(11),3,5,7- ,9-pentaene: ##STR00001## and pharmaceutical compositions thereof. The present invention in particular is directed to the L-tartrate salt, and further to the various polymorphs of the L-tartrate salt, including two distinct anhydrous polymorphs (referred to herein as Forms A and B) and a hydrate polymorph (referred to herein as Form C). In addition, the present invention is also directed to the D-tartrate salt of 5,8,14-triazatetracyclo[10.3.1.0.sup.2,11.0.sup.4,9]-hexadeca-2(11),3,5,7- ,9-pentaene and the various polymorphs thereof; as well as the D,L-tartrate salt thereof and its polymorphs, and the meso-tartrate salt thereof and its polymorphs.
Inventor(s): Bogle; David E. (Jewett City, CT), Williams; Glenn R. (Oaksville, CA), Rose; Peter R. (Ledyard, CT)
Assignee: Pfizer Inc (New York, NY)
Application Number:11/069,724
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,265,119
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,265,119
Patent Claim Types:
see list of patent claims
Compound; Composition; Use;

Drugs Protected by US Patent 7,265,119

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928-001 May 10, 2006 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Pf Prism Cv CHANTIX varenicline tartrate TABLET;ORAL 021928-002 May 10, 2006 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

International Family Members for US Patent 7,265,119

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
African Regional IP Organization (ARIPO) 1473 ➤ Try a Free Trial
Argentina 033635 ➤ Try a Free Trial
Austria 302607 ➤ Try a Free Trial
Australia 2002253482 ➤ Try a Free Trial
Bulgaria 108343 ➤ Try a Free Trial
Bulgaria 66408 ➤ Try a Free Trial
Brazil 0209605 ➤ Try a Free Trial
Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

Subscribe to access the full database, or try a Free Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Moodys
US Army
Federal Trade Commission
Daiichi Sankyo
Accenture

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.